Processa Pharmaceuticals Stock Fundamentals
| PCSA Stock | USD 1.56 0.10 6.02% |
Processa Pharmaceuticals fundamentals help investors to digest information that contributes to Processa Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Processa Stock. The fundamental analysis module provides a way to measure Processa Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Processa Pharmaceuticals stock.
At present, Processa Pharmaceuticals' Interest Expense is projected to decrease significantly based on the last few years of reporting. The current year's Selling General Administrative is expected to grow to about 5.9 M, whereas Gross Profit is forecasted to decline to (233.10). Processa | Select Account or Indicator |
Processa Pharmaceuticals Company Return On Equity Analysis
Processa Pharmaceuticals' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Processa Pharmaceuticals Return On Equity | -1.79 |
Most of Processa Pharmaceuticals' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Processa Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Processa Total Stockholder Equity
Total Stockholder Equity |
|
Based on the latest financial disclosure, Processa Pharmaceuticals has a Return On Equity of -1.7852. This is 92.55% lower than that of the Biotechnology sector and 95.1% lower than that of the Health Care industry. The return on equity for all United States stocks is notably higher than that of the company.
Processa Pharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Processa Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Processa Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Processa Pharmaceuticals competition to find correlations between indicators driving Processa Pharmaceuticals's intrinsic value. More Info.Processa Pharmaceuticals is considered to be number one stock in return on equity category among related companies. It is considered to be number one stock in return on asset category among related companies . At present, Processa Pharmaceuticals' Return On Equity is projected to slightly decrease based on the last few years of reporting.Comparative valuation analysis is a catch-all model that can be used if you cannot value Processa Pharmaceuticals by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Processa Pharmaceuticals' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Processa Pharmaceuticals' earnings, one of the primary drivers of an investment's value.Processa Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Processa Pharmaceuticals' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Processa Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Processa Pharmaceuticals by comparing valuation metrics of similar companies.Processa Pharmaceuticals is currently under evaluation in return on equity category among related companies.
Processa Fundamentals
| Return On Equity | -1.79 | ||||
| Return On Asset | -0.99 | ||||
| Current Valuation | (157.43 K) | ||||
| Shares Outstanding | 2.86 M | ||||
| Shares Owned By Insiders | 11.27 % | ||||
| Shares Owned By Institutions | 1.98 % | ||||
| Number Of Shares Shorted | 35.81 K | ||||
| Price To Book | 0.96 X | ||||
| EBITDA | (11.46 M) | ||||
| Net Income | (11.12 M) | ||||
| Cash And Equivalents | 12.06 M | ||||
| Cash Per Share | 0.76 X | ||||
| Total Debt | 150.55 K | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 8.89 X | ||||
| Book Value Per Share | 3.88 X | ||||
| Cash Flow From Operations | (8.06 M) | ||||
| Short Ratio | 0.44 X | ||||
| Earnings Per Share | (8.48) X | ||||
| Price To Earnings To Growth | (0.12) X | ||||
| Target Price | 80.0 | ||||
| Number Of Employees | 13 | ||||
| Beta | 0.52 | ||||
| Market Capitalization | 4.4 M | ||||
| Total Asset | 5.79 M | ||||
| Retained Earnings | (75.37 M) | ||||
| Working Capital | 4.9 M | ||||
| Net Asset | 5.79 M |
About Processa Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Processa Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Processa Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Processa Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 556.5 K | 584.3 K | |
| Total Revenue | 0.00 | 0.00 | |
| Cost Of Revenue | 222.00 | 210.90 | |
| Stock Based Compensation To Revenue | 1.54 | 1.41 | |
| Sales General And Administrative To Revenue | 12.59 | 10.62 | |
| Research And Ddevelopement To Revenue | 1.51 | 2.35 | |
| Capex To Revenue | (0.01) | (0.01) | |
| Revenue Per Share | 0.02 | 0.02 | |
| Ebit Per Revenue | 12.87 | 13.52 |
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Processa Pharmaceuticals using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Processa Pharmaceuticals Piotroski F Score and Processa Pharmaceuticals Altman Z Score analysis. For information on how to trade Processa Stock refer to our How to Trade Processa Stock guide.You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Complementary Tools for Processa Stock analysis
When running Processa Pharmaceuticals' price analysis, check to measure Processa Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Processa Pharmaceuticals is operating at the current time. Most of Processa Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Processa Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Processa Pharmaceuticals' price. Additionally, you may evaluate how the addition of Processa Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios |
Is Processa Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Processa Pharmaceuticals. If investors know Processa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Processa Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (8.48) | Return On Assets (0.99) | Return On Equity (1.79) |
The market value of Processa Pharmaceuticals is measured differently than its book value, which is the value of Processa that is recorded on the company's balance sheet. Investors also form their own opinion of Processa Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Processa Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Processa Pharmaceuticals' market value can be influenced by many factors that don't directly affect Processa Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Processa Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Processa Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Processa Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.